Free Trial

This company has been marked as potentially delisted and may not be actively trading.

TenX Keane Acquisition (TENK) Competitors

TENK vs. IKT, FTLF, ALTS, FATE, NMRA, IMRX, NKTX, RAPT, GLSI, and ACTU

Should you be buying TenX Keane Acquisition stock or one of its competitors? The main competitors of TenX Keane Acquisition include Inhibikase Therapeutics (IKT), FitLife Brands (FTLF), ALT5 Sigma (ALTS), Fate Therapeutics (FATE), Neumora Therapeutics (NMRA), Immuneering (IMRX), Nkarta (NKTX), Rapt Therapeutics (RAPT), Greenwich LifeSciences (GLSI), and Actuate Therapeutics (ACTU). These companies are all part of the "pharmaceutical products" industry.

TenX Keane Acquisition vs. Its Competitors

Inhibikase Therapeutics (NYSE:IKT) and TenX Keane Acquisition (NASDAQ:TENK) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inhibikase TherapeuticsN/AN/A-$19.03M-$2.67-0.72
TenX Keane AcquisitionN/AN/AN/AN/AN/A

TenX Keane Acquisition's return on equity of 0.00% beat Inhibikase Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Inhibikase TherapeuticsN/A -350.63% -201.82%
TenX Keane Acquisition N/A N/A N/A

In the previous week, Inhibikase Therapeutics had 3 more articles in the media than TenX Keane Acquisition. MarketBeat recorded 3 mentions for Inhibikase Therapeutics and 0 mentions for TenX Keane Acquisition. Inhibikase Therapeutics' average media sentiment score of 0.30 beat TenX Keane Acquisition's score of 0.00 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Inhibikase Therapeutics Neutral
TenX Keane Acquisition Neutral

Inhibikase Therapeutics currently has a consensus price target of $6.50, indicating a potential upside of 236.79%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Inhibikase Therapeutics is more favorable than TenX Keane Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inhibikase Therapeutics
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
TenX Keane Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 70.5% of TenX Keane Acquisition shares are owned by institutional investors. 7.3% of Inhibikase Therapeutics shares are owned by company insiders. Comparatively, 22.9% of TenX Keane Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Inhibikase Therapeutics beats TenX Keane Acquisition on 5 of the 9 factors compared between the two stocks.

Get TenX Keane Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for TENK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TENK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TENK vs. The Competition

MetricTenX Keane AcquisitionHolding Offices Industry SectorNASDAQ Exchange
Market Cap$35.19M$177.44M$1.99B$9.03B
Dividend YieldN/A5.41%13.73%4.07%
P/E RatioN/A2.4812.1720.03
Price / SalesN/A435.632,010,508.86108.98
Price / CashN/A74.7857.0128.59
Price / BookN/A6.473.555.55
Net IncomeN/A$3.67M-$351.12M$248.49M

TenX Keane Acquisition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TENK
TenX Keane Acquisition
N/A$5.29
+1.3%
N/A-53.4%$35.19MN/A0.00N/AGap Down
High Trading Volume
IKT
Inhibikase Therapeutics
1.3227 of 5 stars
$1.85
-5.1%
$6.50
+251.4%
+62.9%$137.53M$260K-0.696
FTLF
FitLife Brands
4.0216 of 5 stars
$13.61
-3.7%
$20.50
+50.6%
-12.7%$132.79M$64.47M16.2020
ALTS
ALT5 Sigma
0.0587 of 5 stars
$7.88
+4.1%
N/AN/A$132.04M$12.53M0.00170Gap Up
FATE
Fate Therapeutics
4.2431 of 5 stars
$1.12
-1.8%
$3.83
+242.3%
-63.9%$130.65M$13.63M-0.75550Analyst Revision
Gap Down
NMRA
Neumora Therapeutics
2.3787 of 5 stars
$0.78
-1.8%
$9.29
+1,087.1%
-92.1%$128.80MN/A-0.49108
IMRX
Immuneering
4.0392 of 5 stars
$3.59
+4.4%
$13.25
+269.1%
+211.0%$123.79M$320K-1.8360Positive News
NKTX
Nkarta
2.0617 of 5 stars
$1.74
+1.8%
$14.33
+723.8%
-66.1%$121.34MN/A-1.15140
RAPT
Rapt Therapeutics
4.1951 of 5 stars
$8.01
+9.3%
$24.00
+199.6%
-63.7%$121.21M$1.53M-0.4280
GLSI
Greenwich LifeSciences
1.4566 of 5 stars
$9.88
+9.2%
$39.00
+294.7%
-39.9%$120.98MN/A-7.843
ACTU
Actuate Therapeutics
2.9841 of 5 stars
$6.74
+10.0%
$20.50
+204.2%
N/A$120.27MN/A0.0010Positive News
High Trading Volume

Related Companies and Tools


This page (NASDAQ:TENK) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners